TITLE:
Metastatic Prostate Cancer under Androgen Deprivation Therapy: Factors Influencing Castration Resistance
AUTHORS:
Modou Ndiaye, Ousmane Sow, Babacar Sine, Omar Gaye, Alioune Sarr, Abdoulaye Ndiath, Cyrille Ze Ondo, Amath Thiam, Ndeye Aissatou Bagayogo, Samba Thiapato Faye, Ndiaga Seck Ndour, Aboubacar Traore, Ngor Mack Thiam, El Hadj Malick Diaw, Yaya Sow, Boubacar Fall, Babacar Diao, Alain Khassim Ndoye
KEYWORDS:
Cancer, Prostate, Androgen Deprivation Therapy, Resistance, Prognoses
JOURNAL NAME:
Open Journal of Urology,
Vol.10 No.7,
July
30,
2020
ABSTRACT: Objective: To evaluate the factors predicting the time to progression to castration-resistant in metastatic prostate cancer under Androgen Deprivation Therapy (ADT) in our center. Patients and Methods: This is a retrospective, descriptive, analytical study in a single center over a period of 2 years. It has interest patients followed for metastasized prostate cancer under ADT. The parameters studied were: epidemiological, clinical, paraclinical, prostate specific antigen (PSA) nadir, time to nadir (TTN) and their link with the castration resistance. Results: The frequency of castration resistant prostate cancer was 28 patients per year. The mean age was 70.4 ± 7.9 years. An ECOG score ≥ 3 was more common as was the cT2c stage. The median of the initial total PSA was 489.6 ng/ml (203.3; 1653.2). All patients had adenocarcinoma. The International Society of Urological Pathology (ISUP) 1 was more frequent. Bone metastases were more frequent. The medians of nadir, TTN and the castration resistance were 19.3 ng/ml (3.7; 102.1), 5.5 months (3; 9) and 11 months (6; 15.3), respectively. The Eastern Cooperative Oncology Group (ECOG) score, clinical stage, metastatic site, the nadir and its TTN influenced the DSR. Age, lymph node involvement, initial total PSA and Gleason score did not influence the castration resistance. Conclusion: ADT should be initiated as soon as possible before an attack of general and/or clinical stage advanced to delay resistance. A drilling should be associated with this hormone therapy as much as possible because of its gain on resistance.